Search results for: 'dmkc+cultur+scienc+2025'

Comprehensive Business Intelligence for Strategic Decision-Making

The All In One Partnering Intelligence Platform

Get unlimited access to our partnering report library conveniently and easily, while maximizing your time and budget

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report offers in-depth insights and exclusive access to discovery-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

Bioinformatics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Microbiome Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

In Vitro Diagnostic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Infectious Vaccine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Stem Cell Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2010 to 2025

Essential Benchmark Data for Dealmakers  | Global coverage | Updated to 2025 | 15+ years of royalty rates | Deal financials | Contract documents | Royalty rate trends

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals